Phase 3 Readout~month

Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva

Indication
Primary Immune Deficiency

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva — CGC Phase 3 Readout | BioSniper